Medha Barbhaiya1, Stephane Zuily2, Yasaman Ahmadzadeh3, Mary-Carmen Amigo4, Tadej Avcin5, Maria Laura Bertolaccini6, D Ware Branch7, Guilherme de Jesus8, Katrien M J Devreese9, Camille Frances10, David Garcia11, Francis Guillemin12, Steven R Levine13, Roger A Levy14, Michael D Lockshin1, Thomas L Ortel15, Surya V Seshan16, Maria Tektonidou17, Denis Wahl2, Rohan Willis18, Ray Naden, Karen Costenbader19, Doruk Erkan1. 1. Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York. 2. Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Université de Lorraine, Inserm, DCAC, and CHRU-Nancy, Nancy, France. 3. Hospital for Special Surgery, New York, New York. 4. ABC Medical Center, Mexico City, Mexico. 5. Children's Hospital, University Medical Center, University of Ljubljana, Ljubljana, Slovenia. 6. King's College London British Heart Foundation Centre of Excellence, London, UK. 7. University of Utah Health, Salt Lake City. 8. Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. 9. Ghent University Hospital, Ghent University, Ghent, Belgium. 10. Tenon Hospital, Paris, France. 11. University of Washington, Seattle. 12. CIC Clinical Epidemiology, APEMAC and CHRU, Inserm, Université de Lorraine, Nancy, France. 13. Downstate Stroke Center, State University of New York Downstate Health Sciences University, Kings County Hospital Center, and Maimonides Medical Center/Jaffe Stroke Center, Brooklyn, New York. 14. Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, and GlaxoSmithKline, Upper Providence, Pennsylvania. 15. Duke University Medical Center, Durham, North Carolina. 16. Weill Cornell Medicine, New York, New York. 17. University of Athens, Athens, Greece. 18. University of Texas Medical Branch, Galveston. 19. Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
OBJECTIVE: An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains. METHODS: During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains. RESULTS: Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification. CONCLUSION: Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.
OBJECTIVE: An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains. METHODS: During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains. RESULTS: Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification. CONCLUSION: Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.
Authors: José A Martínez-Flores; Manuel Serrano; Javier Alfaro; Sergio Mora; Estela Paz-Artal; José M Morales; Antonio Serrano Journal: Anal Chem Date: 2013-11-26 Impact factor: 6.986
Authors: Guilherme R de Jesús; Ashley E Benson; Cecilia B Chighizola; Savino Sciascia; David W Branch Journal: Lupus Date: 2020-09-03 Impact factor: 2.911
Authors: Sara K Tedeschi; Sindhu R Johnson; Dimitrios Boumpas; David Daikh; Thomas Dörner; David Jayne; Diane Kamen; Kirsten Lerstrøm; Marta Mosca; Rosalind Ramsey-Goldman; Corine Sinnette; David Wofsy; Josef S Smolen; Raymond P Naden; Martin Aringer; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2018-02-22 Impact factor: 4.794
Authors: Rohit Aggarwal; Sarah Ringold; Dinesh Khanna; Tuhina Neogi; Sindhu R Johnson; Amy Miller; Hermine I Brunner; Rikke Ogawa; David Felson; Alexis Ogdie; Daniel Aletaha; Brian M Feldman Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Maria Laura Bertolaccini; Olga Amengual; Laura Andreoli; Tatsuya Atsumi; Cecilia B Chighizola; Ricardo Forastiero; Philip de Groot; Gabriella Lakos; Marc Lambert; Pierluigi Meroni; Thomas L Ortel; Michelle Petri; Anisur Rahman; Robert Roubey; Savino Sciascia; Melissa Snyder; Anne E Tebo; Angela Tincani; Rohan Willis Journal: Autoimmun Rev Date: 2014-05-10 Impact factor: 9.754
Authors: Stavros V Konstantinides; Guy Meyer; Cecilia Becattini; Héctor Bueno; Geert-Jan Geersing; Veli-Pekka Harjola; Menno V Huisman; Marc Humbert; Catriona Sian Jennings; David Jiménez; Nils Kucher; Irene Marthe Lang; Mareike Lankeit; Roberto Lorusso; Lucia Mazzolai; Nicolas Meneveau; Fionnuala Ní Áinle; Paolo Prandoni; Piotr Pruszczyk; Marc Righini; Adam Torbicki; Eric Van Belle; José Luis Zamorano Journal: Eur Heart J Date: 2020-01-21 Impact factor: 35.855
Authors: Shawn A Mahmud; Danielle R Bullock; Colleen K Correll; Patricia M Hobday; Mona M Riskalla; Richard K Vehe; Bryce A Binstadt Journal: Pediatr Rheumatol Online J Date: 2022-08-20 Impact factor: 3.413